A study of over 1.1 million births found a U-shaped relationship between early pregnancy hemoglobin levels and severe neonatal morbidity and mortality, with both anemia and erythrocytosis increasing risk.
The FDA has accepted New Drug Applications for rusfertide in polycythemia vera with Priority Review and tirabrutinib for relapsed/refractory primary CNS lymphoma under Accelerated Approval, with PDUFA dates set for Q3 2026 and December 2026 respectively.
The FDA has accepted the New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for polycythemia vera, and granted Priority Review with a PDUFA goal date in the third quarter of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06785870 |
EVAluation of Erythrocytosis PRospEctive Cohort STudy |
NOT_YET_RECRUITING | |
| NCT05833477 |
Tracing Changed Production of Red Blood Cells |
COMPLETED | NA |
| NCT05118048 |
StatStrip Lactate, Hemoglobin, and Hematocrit Meter in Whole Blood |
TERMINATED | |
| NCT04751292 |
HIGH Altitude CArdiovascular REsearch Latin America Population Study |
COMPLETED | |
| NCT02548117 |
H-36731: Finasteride in Management of Elevated Red Blood Cells |
WITHDRAWN | PHASE3 |
| NCT01187108 |
Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru |
COMPLETED | PHASE1/PHASE2 |
